“Rampant” veterinary practice consolidation and software trends
All these factors, and others, impact software decisions. In terms of the players, the Interview focused on Covetrus, Idexx and EzyVet. In the practice information management system (PiMS) space, Covetrus’ Avimark has the highest market share, with 8,500-9,000 customers. However, the company is restricted in terms of the size of hospitals it can serve.
Regarding the chartless and paperless sub-segments, Idexx’s Cornerstone represents the second-biggest market share, with 6,500 to 7,000 customers. The next biggest or equal player is EzyVet, with HQs in New Zealand and Texas. The expert also pointed out Oregon-based DoveLewis.
In other observations, wellness plans are a “hot topic”, with customers increasingly looking to integrate these into their offerings. “What customers are looking for is a way for it to integrate within Avimark, Infinity, EzyVet, whatever PiMS they have to make it easier for them. Not only that, one of the biggest players within the industry, VCP, what they do is they actually help collect the charges.”
The significance of Chewy’s entry into the vet prescription market and prescription-fulfilment services was also discussed, with it being noted that PiMS integrations with pharmacies are “just starting to take off”. The expert said they could see the company launching a wellness offering, but that the hard part will be partnering with a clinic.
In their closing remarks, data consolidation was flagged as a “huge problem within the industry”, with the expert commenting that “if you can incorporate that into whatever offering, whether it’s wellness, whether it’s PiMS or whatever, fast, it’s going to be a differentiator because it has not been figured out yet.”
To access all the human insights in Third Bridge Forum’s Interview, click here to view the full transcript.
The information used in compiling this document has been obtained by Third Bridge from experts participating in Forum Interviews. Third Bridge does not warrant the accuracy of the information and has not independently verified it. It should not be regarded as a trade recommendation or form the basis of any investment decision.
For any enquiries, please contact sales@thirdbridge.com
